Skip to main content
Quest Diagnostics

Insulin Resistance in Early Pregnancy and Development of Preeclampsia

SRI 2026

73rd Annual Scientific Meeting of the Society for Reproductive Investigation (SRI)

San Juan, Puerto Rico, March 24-28 2026

Poster presentation: Insulin Resistance in Early Pregnancy and Development of Preeclampsia

Authors: Wild RA, LeBlanc E, Arellano AR, Bare LA, Alagia AP, McPhaul MJ

Medical Specialty: Cardiology, Endocrinology,  Cardiovacular disease, Women's Health, OB/GYN

Related content

Publication
Highly atherogenic lipid particles are associated with preeclampsia after successful fertility treatment for obese women who have unexplained infertility
Publication
Weight Loss Before Conception: Effects on Atherogenic Apolipoprotein Lipid Particles and Endothelial Function During Pregnancy
Audio Podcast
The Insulin Resistance Revolution: The Key to Preventing Chronic Conditions
On-Demand Webinar
The Link Between Reproductive Abnormalities and Cardiometabolic Conditions
On-Demand Webinar
Demystifying the Diagnosis of Polycystic Ovary Syndrome

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.